Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Gilead Sciences (NASDAQ:GILD) on Wednesday announced a collaboration with the Swiss non-profit The Global Fund to accelerate ...

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime ...

Detailed price information for Primo Water Corp (PRMB-N) from The Globe and Mail including charting and trades.